In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Talon Therapeutics, Inc.

http://www.talontx.com

Latest From Talon Therapeutics, Inc.

Chinese Firms Look Inward To Access Innovation

Two recent licensing deals involving Chinese firms underscore the record level of agreements being inked between innovative domestic biotechs and generic drug makers, at a time when corporate valuations and geopolitical tensions have made cross-border transactions harder to grab.

China Deals

UCB’s Bimzelx Impresses In Psoriatic Arthritis Amid US Psoriasis Approval Delay

UCB’s Bimzelx has forged ahead with success in a late-stage psoriatic arthritis trial while it still awaits US approval for psoriasis, a hotly anticipated blockbuster indication.

Clinical Trials Companies

Competition and Price Cuts Slow Strong IO Momentum In China

While strong growth in China's immuno-oncology sector continued in the last quarter, the momentum appears to be slowing, affecting by multiple factors including intense competition in the sector and price cuts related to reimbursement listing, while regulatory authorities have already warned about what they see as the wasting of resources on "redundant" development activities. 

China Sales & Earnings

Two More IO Drugs Coming In China As Hengrui, Lee’s File NDAs

The latest immuno-oncology newcomers from Lee’s Pharma and Jiangsu Hengrui will further choke an already crowded field in China if they are approved following recent filings.

China Approvals
See All

Company Information

  • Other Names / Subsidiaries
    • Hana Biosciences, Inc.
UsernamePublicRestriction

Register